Sangamo Therapeutics' GAAP loss for 3 months of 2022 was $43.977 million, down 4.3% from $45.939 million in the prior year. Revenue increased 7.4% to $28.231 million from $26.28 million a year earlier.
Sangamo Therapeutics' GAAP loss for 3 months of 2022 was $43.977 million, down 4.3% from $45.939 million in the prior year. Revenue increased 7.4% to $28.231 million from $26.28 million a year earlier. 
investor.sangamo.com
English (US) 